

Volume 31, Issue 1

January 1, 2013

Journal of clinical oncology : official journal  
v. 31, no. 1 (Jan. 1 2013)  
General Collection  
W1 JO5894H  
2013-01-22 13:44:49

# JOURNAL OF CLINICAL ONCOLOGY

Official Journal of the  
American Society of Clinical Oncology

PROPERTY OF THE  
NATIONAL  
LIBRARY OF  
MEDICINE



Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed? *M.J. Overman et al.* Editorial: *J. Peppercorn*

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer. *S. Gourgou-Bourgade et al.* Editorial: *A.H. Ko et al.*

Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight Need for Strict Adherence to Screening Schedule. *A.N. Rosenthal et al.* Editorial: *K.C. Long et al.*

Pegylated Liposomal Doxorubicin, Rituximab, Cyclophosphamide, Vincristine, and Prednisone in AIDS-Related Lymphoma. *A.M. Levine et al.*

Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery. *R. Soffiatti et al.* Editorial: *A.J. Khan et al.*

Prognostic Impact of Pregnancy After Breast Cancer According to Estrogen Receptor Status. *H.A. Azim Jr et al.*

...way: Targeting B-Cell Receptor Signaling for ...  
...tinib Induces Impressive Responses in B-Cell ...  
...

020150

JOURNAL OF CLINICAL ONCOLOGY

2013 VOLUME 31 ISSUE 1

SISAC



0732-183X(2013)31:1:1-F

28803526



**DOCKET  
ALARM**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

Now Enrolling



Rilotumumab in  
MET-positive gastric cancer  
**RILOMET-1**


RILOMET-1: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-Line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

**Primary Endpoint:**

- Overall survival (OS)

**Secondary Endpoints:**

- Progression-free survival (PFS)
- Time to progression (TTP)
- Overall response rate (ORR), disease control rate (DCR), and time to response (TTR)
- Safety and immunogenicity



Rilotumumab is an investigational agent that has not been approved by regulatory agencies for the use under investigation for this trial.

**Key Inclusion Criteria:**

- Pathologically confirmed unresectable locally advanced or metastatic gastric or GEJ adenocarcinoma
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Tumor MET-positive by centralized immunohistochemistry (IHC)
- Tumor Human Epidermal Growth Factor Receptor 2 (HER2)-negative

**For Additional Information:**

- Amgen Call Center: (866) 57-AMGEN or (866) 572-6436
- [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov) (NCT01697072)



1. Iveson T, et al. *Eur J Cancer*. 2011;47(Suppl. 1):S443. Oral presentation at 2011 European Multidisciplinary Cancer Congress; Sept 23-27, 2011; Stockholm, Sweden. Abstract #6504.  
2. Zhu M, et al. *J Clin Oncol*. 2012;30(15 Suppl):2535. Poster discussion at 2012 American Society of Clinical Oncology Annual Meeting; Jun 1-5, 2012; Chicago, IL. Abstract #2535.  
3. Davidenko I, et al. *Ann Oncol*. 2012;23(Suppl. 9):ix230. Poster presentation at European Society of Medical Oncology 2012 Congress; Sept 28-Oct 2, 2012; Vienna, Austria. Abstract 687P.

©2013 Amgen Inc. All rights reserved.



# Tell Your Patients About ASCO's Cancer.Net Mobile App

HELP YOUR PATIENTS  
MANAGE THEIR  
TREATMENT AND CARE



Available for **FREE**  
on iPad, iPhone,  
and Android Devices

Scan to Download  
in Your Respective  
App Store



Learn more at [cancer.net/app](http://cancer.net/app)

Cancer.Net

Doctor-Approved Patient Information from ASCO®

# JOURNAL OF CLINICAL ONCOLOGY

Official Journal of the  
American Society of Clinical Oncology

## CONTENTS

### EDITORIALS

#### Toward Improved Understanding of the Ethical and Clinical Issues Surrounding Mandatory Research Biopsies

Jeffrey Peppercorn (see article on page 17) ..... 1

#### Achieving the Best of Both Worlds

Andrew H. Ko and David Cella (see article on page 23) ..... 3

#### Improving T-Cell Therapy for Epstein-Barr Virus Lymphoproliferative Disorders

Catherine M. Bollard (see article on page 39) ..... 5

#### Screening for Familial Ovarian Cancer: A Ray of Hope and a Light to Steer by

Kara C. Long and Noah D. Kauff (see article on page 49) ..... 8

#### On the Merits and Limitations of Whole-Brain Radiation Therapy

Atif J. Khan and Adam P. Dicker (see article on page 65) ..... 11

### COMMENTS AND CONTROVERSIES

#### Curability of Advanced Indolent or Low-Grade Follicular Lymphomas: Time for a New Paradigm?

Fernando Cabanillas ..... 14

continued on following page

*Journal of Clinical Oncology* (ISSN 0732-183X) is published 36 times a year, three times monthly, by the American Society of Clinical Oncology, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Periodicals postage is paid at Alexandria, VA, and at additional mailing offices. Publication Mail Agreement Number 863289.

Editorial correspondence should be addressed to Stephen A. Cannistra, MD, *Journal of Clinical Oncology*, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Phone: 703-797-1900; Fax: 703-684-8720. E-mail: jco@asco.org; Internet: www.jco.org.

**POSTMASTER:** ASCO members should send changes of address to American Society of Clinical Oncology, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Nonmembers should send changes of address to *Journal of Clinical Oncology* Customer Service, 2318 Mill Road, Suite 800, Alexandria, VA 22314.

2013 annual subscription rates, effective September 1, 2012: United States and possessions: individual, \$578 one year, \$1,098 two years; single issue, \$40. International: individual, \$802 one year, \$1,524 two years; single issue, \$50. Institutions: bundled (print + online): Tier 1: \$899 US, \$1,248 Int'l; Tier 2: \$1,052 US, \$1,395 Int'l; Tier 3: \$1,519 US, \$1,849 Int'l; Tier 4: contact JCO for quote. Institutions: online only, worldwide: Tier 1, \$769; Tier 2: \$897; Tier 3, \$1,295; Tier 4: contact JCO for quote. See www.jco.org/ratecard for descriptions of each tier. Student and resident: United States and possessions: \$289; all other countries, \$401. To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the signature of program/residency coordinator on institution letterhead. Orders will be billed at individual rate until proof of status is received. Current prices are in effect for back volumes and back issues. Back issues sold in conjunction with a subscription rate are on a prorated basis. Subscriptions are accepted on a 12-month basis. Prices are subject to change without notice. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability. JCO Legacy Archive (electronic back issues from January 1983 through December 1998) is also available; please inquire.

## ORIGINAL REPORTS

## Ethics

**Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?**

Michael J. Overman, Janhavi Modak, Scott Kopetz, et al (see editorial on page 1) ..... 17

## Gastrointestinal Cancer

**1 Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial**

Sophie Gourgou-Bourgade, Caroline Bascoul-Mollevi, Françoise Desseigne, et al (see editorial on page 3) ..... 23

**Postoperative Adjuvant Chemotherapy Use in Patients With Stage II/III Rectal Cancer Treated With Neoadjuvant Therapy: A National Comprehensive Cancer Network Analysis**

Polina Khrizman, Joyce C. Niland, Anna ter Veer, et al ..... 30

## Immunotherapy

**Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1-Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation**

Vanya Icheva, Simone Kayser, Daniel Wolff, et al (see editorial on page 5) ..... 39

## Gynecologic Cancer

**Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule**

Adam N. Rosenthal, Lindsay Fraser, Ranjit Manchanda, et al (see editorial on page 8) ..... 49

## AIDS-Related Cancer

**2 Pegylated Liposomal Doxorubicin, Rituximab, Cyclophosphamide, Vincristine, and Prednisone in AIDS-Related Lymphoma: AIDS Malignancy Consortium Study 047**Alexandra M. Levine, Ariela Noy, Jeannette Y. Lee, et al (listen to the podcast by Dr Smith at [www.jco.org/podcasts](http://www.jco.org/podcasts)) ..... 58

## Neurooncology

**1 2 A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life Results**Riccardo Soffietti, Martin Kocher, Ufuk M. Abacioglu, et al (see editorial on page 11; listen to the podcast by Dr Osoba at [www.jco.org/podcasts](http://www.jco.org/podcasts)) ..... 65

## Breast Cancer

**Prognostic Impact of Pregnancy After Breast Cancer According to Estrogen Receptor Status: A Multicenter Retrospective Study**

Hatem A. Azim Jr, Niels Kroman, Marianne Paesmans, et al ..... 73

continued on following page

## Radiation Oncology

- Use of Radiation Therapy in the Last 30 Days of Life Among a Large Population-Based Cohort of Elderly Patients in the United States**  
B. Ashleigh Guadagnolo, Kai-Ping Liao, Linda Elting, et al ..... 80

## Hematologic Malignancies

- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies**  
Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman, et al (see article on page 128) ..... 88

- I Deregulated Expression of *EVII* Defines a Poor Prognostic Subset of *MLL*-Rearranged Acute Myeloid Leukemias: A Study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group**  
Stefan Gröschel, Richard F. Schlenk, Jan Engelmann, et al ..... 95

- Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial**  
Gandhi Damaj, Rémy Gressin, Krime Bouabdallah, et al ..... 104

## Palliative and Supportive Care

- I Parenteral Hydration in Patients With Advanced Cancer: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial**  
Eduardo Bruera, David Hui, Shalini Dalal, et al ..... 111

## Pediatric Oncology

- I Absolute Risk Prediction of Second Primary Thyroid Cancer Among 5-Year Survivors of Childhood Cancer**  
Stephanie A. Kovalchik, Cécile M. Ronckers, Lene H.S. Veiga, et al ..... 119

## UNDERSTANDING THE PATHWAY

- Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies**  
Adrian Wiestner (see article on page 88) ..... 128

## ASCO SPECIAL ARTICLE

- Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology**  
Bruce J. Roth, Lada Krilov, Sylvia Adams, et al ..... 131

## ART OF ONCOLOGY

- How They Do This**  
Abby R. Rosenberg ..... 162

## CORRESPONDENCE

- Capturing Data on Colostomy Formation in Anal Cancer**  
Rob Glynn-Jones, Sandy Beare, Rubina Begum, et al ..... 164
- Reply to R. Glynn-Jones et al**  
Didier Peiffert, Laetitia Tournier-Rangear, Jean-Pierre Gérard, et al ..... 165

*continued on following page*

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.